Your search matched 12 results
At this year’s Digital Medicine & MedTech Showcase (part of Biotech Showcase), a panel of digital therapeutics (DTx) experts illuminated the status and future of their work, moderated by Syneos Health Commercial Solutions Chief Strategy Officer, Baba Shetty.
Where will digital therapeutics or DTx be in five years?
What healthcare stakeholders should think about when it comes to DTx partnerships and how DTx developers can satisfy diverse stakeholder needs.
Is the market prepared for DTx?
Digital Therapeutics at the Crossroads | Perspectives
Payer perspectives on reimbursement hurdles can help DTx companies map the journey to real-world utilization and market success.
Digital therapeutics, or DTx, are distinct from digital health products, and are driven by software programs that can be prescribed to prevent, manage, or treat a medical disorder or disease, as stated by the Digital Therapeutics Alliance.
With there being so many different stakeholders, including patients, providers and payers, panelists at the 2019 Digital Medicine & MedTech Showcase pointed to a number of different adoption roadblocks—and successes.
Paving the Way | Perspectives
Is Europe catching up (or pioneering the way) in digital therapeutics?
Recognizing that the impact of multiple sclerosis (MS) goes beyond the conventionally recognized symptoms, Sanofi has announced a new app to support people with the disease—specifically, their mental health.
There are three potential solutions for pharma, device, or DTx marketers to consider based on trends we’ll see in the year ahead.
How DTx Developers Can Satisfy Diverse Stakeholder Needs | Perspectives
All signs point to a breakthrough year for digital therapeutics.
Diabetes is an epidemic with a devastating physical, emotional and financial toll on those it impacts.